Qualigen Therapeutics, Inc. (QLGN)

NASDAQ: QLGN · IEX Real-Time Price · USD
0.579
-0.003 (-0.60%)
At close: Feb 26, 2024, 4:00 PM
0.524
-0.055 (-9.51%)
After-hours: Feb 27, 2024, 7:31 PM EST
-0.60%
Market Cap 2.89M
Revenue (ttm) 4.62M
Net Income (ttm) -17.34M
Shares Out 5.18M
EPS (ttm) -3.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 171,539
Open 0.584
Previous Close 0.582
Day's Range 0.468 - 0.584
52-Week Range 0.451 - 1.380
Beta 0.08
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2023

About QLGN

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 31
Stock Exchange NASDAQ
Ticker Symbol QLGN
Full Company Profile

Financial Performance

In 2022, QLGN's revenue was $4.98 million, a decrease of -11.85% compared to the previous year's $5.65 million. Losses were -$18.64 million, 4.15% more than in 2021.

Financial Statements

News

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w...

3 months ago - GlobeNewsWire

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w...

4 months ago - GlobeNewsWire

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models

4 months ago - GlobeNewsWire

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Two p osters include data on potential clinical biomarkers and transcriptomic data associated with QN-302's mechanism of action

5 months ago - GlobeNewsWire

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers w...

6 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack ® diagnostics business for approximately $5 mi llion in all cash trans...

7 months ago - GlobeNewsWire

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and d emonstrates leadership in G4-targeting therapies for areas of high unmet nee...

7 months ago - GlobeNewsWire

Qualigen Therapeutics Divests FastPack® Diagnostics Business

All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen's strategic priority on therapeutics

7 months ago - GlobeNewsWire

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds

9 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adul...

10 months ago - GlobeNewsWire

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer

10 months ago - GlobeNewsWire

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

CARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for a...

11 months ago - GlobeNewsWire

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for a...

11 months ago - GlobeNewsWire

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

In V ivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type

11 months ago - GlobeNewsWire

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for a...

1 year ago - GlobeNewsWire

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for a...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Data demonstrates potential anti-RAS activity with Qualigen's novel RAS small molecule in both pancreatic and breast cancer in vivo models

1 year ago - GlobeNewsWire

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

S100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models

1 year ago - GlobeNewsWire

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for ad...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for ad...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for ad...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for ad...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for ad...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for ad...

1 year ago - GlobeNewsWire

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for ad...

1 year ago - GlobeNewsWire